The Cobas vivoDx MRSA test uses new bacteriophage technology based on bioluminescence to detect bacterial colonization in nasal swabs.
The German company reported its quarterly earnings for the first time as a public company, following the completion of its IPO on Nov. 7.
The companies are developing a blood-based assay for differentiating lung cancer from benign disease in patients testing positive in low-dose CT screens.
Though the pace of Quest's acquisitions has slowed this year, the latest deal with BCL continues a string of activities resulting from the implementation of PAMA.
In the long term, the company is developing a plan to create more tests based on its technology, which digitizes blood samples and turns them into images.
The grants were awarded through the organization's Diagnostic Accelerator, a partnership between the charity and various philanthropic partners.
The firm is offering total consideration of $1,018.36 per $1,000 for notes tendered by Dec. 2, which includes an early tender premium of $30 per $1,000.
The firms are combining Caris' somatic and Ambry's germline testing to provide clinicians with information on patients' cancers.
The Dutch companies will use sequencing- and machine learning-based methods to quantify genomic instability-causing mutations in blood cells.
The firm said that its panel enables receipt of results for life-threatening conditions, such as sepsis and bacteremia, within about 11 minutes at the point of care.
Veracyte has also acquired Nanostring's Prosigna breast cancer and LymphMark lymphoma assays and plans to develop diagnostic tests using the nCounter platform.
The LCD will provide coverage for the Decipher Prostate Biopsy genomic test for men with both favorable and unfavorable intermediate-risk prostate cancer.
The clearance covers tests made by the firm's joint venture for manufacturing, CoSara Diagnostics, in its facility in Ranoli, India.
ArcherDx will develop in vitro diagnostic tests, including companion diagnostics, to run on Illumina's NextSeq 550Dx next-generation sequencing system.
The platform matches a patient's medical history and other data with national guidelines to recommended medically actionable genetic tests.
BTIG gave Centogene a Buy rating, while SVB Leerink and Evercore ISI each gave the company an Outperform rating.
Of the 28 companies in the index, 21 companies' share prices increased while the share values of 7 declined month over month.
The Genetron Health S5 NGS system is based on the Thermo Fisher Scientific Ion GeneStudio S5 and will be accompanied by Genetron-developed assays.
The companies will develop an integrated clinical pathology solution with plans to submit a 510(k) application to the US Food and Drug Administration.
The companies aim to develop technologies for interpreting cancer genome data, with a focus on linking genetic profiles with treatment responses.